Merck drops up to $610M on neuro disease-focused Caraway Therapeutics
Biohaven hopes to muscle in on Ozempic with a different type of weight loss drug
AstraZeneca’s Imfinzi Phase III trial raises trial design questions
Teva granted pretrial appeal in high-stakes Copaxone kickbacks case *please scroll down for all the latest news*
